ALT
Price
$3.89
Change
-$0.15 (-3.71%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
356.56M
20 days until earnings call
Intraday Buy/Sell Signals
CLDX
Price
$26.70
Change
-$1.21 (-4.34%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
1.85B
14 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

ALT vs CLDX

Header iconALT vs CLDX Comparison
Open Charts ALT vs CLDXBanner chart's image
Altimmune
Price$3.89
Change-$0.15 (-3.71%)
Volume$51.28K
Capitalization356.56M
Celldex Therapeutics
Price$26.70
Change-$1.21 (-4.34%)
Volume$8.19K
Capitalization1.85B
ALT vs CLDX Comparison Chart in %
ALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALT vs. CLDX commentary
Oct 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALT is a Hold and CLDX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 22, 2025
Stock price -- (ALT: $4.04 vs. CLDX: $27.91)
Brand notoriety: ALT and CLDX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALT: 84% vs. CLDX: 70%
Market capitalization -- ALT: $356.56M vs. CLDX: $1.85B
ALT [@Biotechnology] is valued at $356.56M. CLDX’s [@Biotechnology] market capitalization is $1.85B. The market cap for tickers in the [@Biotechnology] industry ranges from $109.29B to $0. The average market capitalization across the [@Biotechnology] industry is $2.07B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALT’s FA Score shows that 0 FA rating(s) are green whileCLDX’s FA Score has 0 green FA rating(s).

  • ALT’s FA Score: 0 green, 5 red.
  • CLDX’s FA Score: 0 green, 5 red.
According to our system of comparison, CLDX is a better buy in the long-term than ALT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALT’s TA Score shows that 7 TA indicator(s) are bullish while CLDX’s TA Score has 4 bullish TA indicator(s).

  • ALT’s TA Score: 7 bullish, 2 bearish.
  • CLDX’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, ALT is a better buy in the short-term than CLDX.

Price Growth

ALT (@Biotechnology) experienced а +1.76% price change this week, while CLDX (@Biotechnology) price change was +5.44% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.72%. For the same industry, the average monthly price growth was +9.91%, and the average quarterly price growth was +61.40%.

Reported Earning Dates

ALT is expected to report earnings on Nov 11, 2025.

CLDX is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (-2.72% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CLDX($1.85B) has a higher market cap than ALT($357M). CLDX YTD gains are higher at: 10.447 vs. ALT (-43.967). ALT has higher annual earnings (EBITDA): -88.03M vs. CLDX (-231.4M). CLDX has more cash in the bank: 630M vs. ALT (183M). CLDX has less debt than ALT: CLDX (3.03M) vs ALT (15.8M). CLDX has higher revenues than ALT: CLDX (5.79M) vs ALT (20K).
ALTCLDXALT / CLDX
Capitalization357M1.85B19%
EBITDA-88.03M-231.4M38%
Gain YTD-43.96710.447-421%
P/E RatioN/AN/A-
Revenue20K5.79M0%
Total Cash183M630M29%
Total Debt15.8M3.03M521%
FUNDAMENTALS RATINGS
ALT vs CLDX: Fundamental Ratings
ALT
CLDX
OUTLOOK RATING
1..100
2417
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
56
Fair valued
PROFIT vs RISK RATING
1..100
10072
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
6343
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CLDX's Valuation (56) in the Biotechnology industry is somewhat better than the same rating for ALT (96) in the Miscellaneous Commercial Services industry. This means that CLDX’s stock grew somewhat faster than ALT’s over the last 12 months.

CLDX's Profit vs Risk Rating (72) in the Biotechnology industry is in the same range as ALT (100) in the Miscellaneous Commercial Services industry. This means that CLDX’s stock grew similarly to ALT’s over the last 12 months.

CLDX's SMR Rating (97) in the Biotechnology industry is in the same range as ALT (98) in the Miscellaneous Commercial Services industry. This means that CLDX’s stock grew similarly to ALT’s over the last 12 months.

CLDX's Price Growth Rating (43) in the Biotechnology industry is in the same range as ALT (63) in the Miscellaneous Commercial Services industry. This means that CLDX’s stock grew similarly to ALT’s over the last 12 months.

CLDX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ALT (100) in the Miscellaneous Commercial Services industry. This means that CLDX’s stock grew similarly to ALT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALTCLDX
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
75%
Momentum
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bullish Trend 2 days ago
67%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
82%
Declines
ODDS (%)
Bearish Trend 6 days ago
87%
Bearish Trend 16 days ago
79%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
80%
Aroon
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
76%
View a ticker or compare two or three
Interact to see
Advertisement
ALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MCBI22.500.62
+2.83%
Mountain Commerce Bancorp Inc.
SALRF62.90N/A
N/A
Salmar ASA
AIIXY30.63N/A
N/A
Aixtron SE
BIMT2.20N/A
N/A
Bitmis Corp
BYDDY13.29-0.36
-2.64%
BYD Co., Ltd.

ALT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALT has been loosely correlated with ACHV. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ALT jumps, then ACHV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALT
1D Price
Change %
ALT100%
+1.00%
ACHV - ALT
48%
Loosely correlated
+3.00%
INDP - ALT
45%
Loosely correlated
-7.95%
KROS - ALT
39%
Loosely correlated
+1.45%
AMRN - ALT
38%
Loosely correlated
-1.53%
CLDX - ALT
36%
Loosely correlated
+0.87%
More

CLDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLDX has been loosely correlated with BEAM. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if CLDX jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLDX
1D Price
Change %
CLDX100%
+0.87%
BEAM - CLDX
54%
Loosely correlated
-2.38%
XNCR - CLDX
52%
Loosely correlated
-3.72%
RVMD - CLDX
51%
Loosely correlated
-0.96%
ARCT - CLDX
51%
Loosely correlated
+7.67%
OCUL - CLDX
51%
Loosely correlated
-3.37%
More